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Measuring endogenous changes in
serotonergic neurotransmission with [11C]
Cimbi-36 positron emission tomography
in humans
Sofi da Cunha-Bang1, Anders Ettrup1, Brenda Mc Mahon1, Anine Persson Skibsted1, Martin Schain1, Szabolcs Lehel2,
Agnete Dyssegaard1, Louise Møller Jørgensen1, Kirsten Møller3, Nic Gillings2, Claus Svarer1 and Gitte M. Knudsen1
Abstract
Developing positron emission tomography (PET) radioligands for the detection of endogenous serotonin release will
enable the investigation of serotonergic deficits in many neuropsychiatric disorders. The present study investigates
how acute challenges that aim to increase or decrease cerebral serotonin levels affect binding of the serotonin 2A
receptor (5-HT2AR) agonist radioligand [
11C]Cimbi-36. In a randomized, double-blind, placebo-controlled, three-arm
design, 23 healthy volunteers were PET scanned twice with [11C]Cimbi-36: at baseline and following double-blind
assignment to one of three interventions (1) infusion of the selective serotonin reuptake inhibitor (SSRI) citalopram
preceded by oral dosing of the 5-HT1AR antagonist pindolol, (n= 8) (2) acute tryptophan depletion (ATD) (n= 7) and
(3) placebo (n= 8). Two-sample t-tests revealed no significant group differences in percent change of neocortical [11C]
Cimbi-36 binding from baseline to intervention between placebo and citalopram/pindolol (p= 0.4) or between
placebo and ATD (p= 0.5). Notably, there was a significantly larger within-group variation in 5-HT2AR binding after
intervention with citalopram/pindolol, as compared with placebo (p= 0.007). These findings suggest that neither ATD
nor a combination of citalopram and pindolol elicit acute unidirectional changes in serotonin levels sufficient to be
detected with [11C]Cimbi-36 PET in neocortex. We suggest that the large interindividual variation in 5-HT2AR binding
after citalopram/pindolol reflects that after an acute SSRI intervention, individuals respond substantially different in
terms of their brain serotonin levels. Our observation has a potential impact for the understanding of patient
responses to SSRI.
Introduction
Serotonergic neurotransmission is implicated in cogni-
tive and emotional processes, and altered serotonin sig-
nalling is thought to contribute to a variety of disorders
such as depression, addiction, schizophrenia, and anxiety.
The development of novel methods to examine the
serotonin system in the human brain is important because
they can give important insights into the serotonergic
mechanisms involved in the pathophysiology of neu-
ropsychiatric disorders.
Positron emission tomography (PET) is a neuroimaging
technique with unsurpassed selectivity and sensitivity to
quantify neuroreceptors in vivo. PET can be used to
measure dynamic changes in neurotransmission that
occur in response to endogenous fluctuations in neuro-
transmitter levels or to experimental challenges1.
Appropriate PET radioligands enables the detection of
endogenous neurotransmitter release, i.e. radioligand
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binding is inversely correlated with in vivo concentration
of neurotransmitters2. Radioligand agonists are hypothe-
sised to be superior to antagonists for the detection of
acute neurotransmitter release because of differential
receptor-affinity states2. For the dopamine system, it has
been reported that D2/D3 receptor agonist radioligands
are more sensitive to endogenous changes in dopamine
than antagonist radioligands3. This difference has been
explained by agonist radioligands binding to the high
affinity state receptor only, inducing competition with
endogenous neurotransmitters2. Accordingly, it was
recently shown in non-human primates that the serotonin
2A (5-HT2A) receptor agonist radioligand [
11C[Cimbi-36
is more sensitive to serotonin release than the antagonist
5-HT2A receptor radioligand [
11C]MDL 1009074.
In humans, several PET serotonergic radioligand studies
have failed to show convincing radioligand displacement
after drug-induced changes in brain serotonin levels2.
Two studies with the partial agonist radiotracer for the 5-
HT1A receptor ([
11C]CUMI) found either no change5 or
an unexpected increase in radioligand binding6. Likewise,
the binding of the 5-HT1B partial agonist radioligand [
11C]
AZ10419369 increased after an acute challenge with a
selective serotonin reuptake inhibitor (SSRI) in humans7.
It was suggested that the unexpected increase in radio-
tracer binding in postsynaptic regions was caused by sti-
mulation of the 5-HT1A and 5-HT1B autoreceptors in the
raphe nuclei, which led to a subsequent inhibition of
serotonin release in the terminals6,7.
The aim of this study was to assess the sensitivity of
[11C]Cimbi-36 binding to acute changes in serotonin
levels in the healthy human brain. In a pseudo-rando-
mized, double-blind, placebo-controlled, 3-arm design,
healthy volunteers were scanned with [11C]Cimbi-36 PET
at baseline and following intervention with either placebo,
the SSRI citalopram combined with a 5-HT1A receptor
antagonist pindolol, or acute tryptophan depletion (ATD).
We hypothesised that citalopram/pindolol would increase
brain serotonin levels and be associated with a decrease in
[11C]Cimbi-36 binding and conversely, that ATD would
decrease brain serotonin levels and thereby increase [11C]
Cimbi-36 binding.
Materials and methods
Study design
This randomized double-blind, placebo-controlled
intervention study was approved by the Ethics commit-
tee for the Capital Region of Denmark (Journal number:
H-4-2012-105), and the first-in-human use of [11C]Cimbi-
36 was approved by the Danish Health and Medicines
Authority (EudraCT number: 2012-002056-16). Prior to
initiation, the trial was registered for public access at
clinicaltrials.gov (Identifier: NCT01778686). Twenty-four
healthy volunteers were PET scanned twice with [11C]
Cimbi-36 at baseline and following random assignment to
one of three groups: eight subjects received the SSRI
citalopram in combination with the 5-HT1A receptor
antagonist pindolol, eight subjects received ATD and
eight subjects received placebo. Sample size was not based
on test-retest [11C]Cimbi-36, because this study was part
of the first study done in humans with [11C]Cimbi-36. The
study took place at the Neurobiology Research Unit
(NRU), Department of Radiology and PET and Cyclotron
Unit of the Copenhagen University Hospital Rig-
shospitalet, Copenhagen, Denmark, from January to
October 2013.
Subjects
Healthy volunteers were recruited through online
advertisements (www.forsogsperson.dk) and paper
advertisements on bulletin boards at universities. Inter-
ested individuals signed up electronically informing their
contact details, age, gender and demographic variables,
which are stored in a database accessible for researchers at
NRU to enroll possible participants for brain scanning
studies. Exclusion criteria were current or lifetime history
of psychiatric disorder, medical or neurological disease,
severe head trauma, alcohol or substance abuse, as well as
severe visual or hearing impairment and contraindications
for MRI. No participant had any medical or neurological
illness according to history, routine blood biochemistry
and physical examination, evaluated on the day of scan-
ning. The participants took no medications, except for
seven women who used hormonal contraceptives and one
participant who reported taking antihistamines. None of
the participants had been exposed to psychotropic med-
ications. All had a negative on urine drug screen (Rapid
Response Multi-Drug; BTNX Inc., Toronto, Ontario,
Canada), and all female subjects had a negative urine
pregnancy test on the day of scanning. The participants
showed no signs of psychopathology according to the
Symptom Checklist Revised (SCL-92, Global Severity
Index score, mean score ± SD: 0.21 ± 0.21)8. All partici-
pants provided written informed consent following full
description of the procedures and received monetary
compensation for their participation. One subject in the
ATD group was excluded from the analysis after suffering
an allergic reaction during the intervention scan. This
subject was referred to an allergist consultant and
examinations excluded that [11C]Cimbi-36 was the cause
of the allergic reaction. Eight subjects (placebo group)
were also included in a previous study evaluating the test-
retest reliability of [11C]Cimbi-369.
Serotonergic interventions and procedure
Each subject participated in two PET experiments with
[11C]Cimbi-36. The participants were scanned at baseline,
and approximately four weeks later they were scanned
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following intervention or placebo. An overview and tim-
ing of the interventions are shown in Table 1. During PET
scanning, subjects were monitored with 3-lead electro-
cardiography continuously and non-invasive measure-
ments of oxygen saturation and blood pressure at regular
intervals. In one of the PET scans (baseline scan, placebo
group) the scanner failed to start correctly. The time
course of the first three minutes of tissue time-activity
curves from this scan were interpolated from the subject’s
intervention scan using the shape of the uptake curve
from the same subject intervention scan while scaling to
the radioactive concentration obtained after the initial
missing three minutes of the baseline scan.
In order to elevate brain serotonin levels, eight subjects
received an intravenous administration of citalopram
immediately before the intervention scan (starting
30 minutes before the scan). Prior to this, these subjects
received the 5-HT1A/1B receptor antagonist pindolol
(Hexapindol®) to block the autoreceptors and thus inhibit
the raphe nuclei-mediated response that could decrease
serotonergic firing rates in response to SSRI-induced rise
in serotonin levels. The subjects were instructed by blin-
ded investigators to take either placebo or pindolol in a
dose escalation regime to minimize side effects. They took
three daily pindolol doses of 2.5 mg, 5 mg, and 7.5 mg,
three days, two days, and one day before the intervention
day, respectively. On the intervention day, they took
7.5 mg pindolol in the morning and again approximately
one hour before the [11C]Cimbi-36 scanning. The
16 subjects who were not randomized to this group
received placebo tablets in a corresponding regime. The
randomization and preparation of pindolol/placebo pre-
treatment were undertaken by two unblinded research
administrators, who were not otherwise involved in the
study. Before the subjects left the research facilities after
the baseline scan, they received an envelope containing
Hexapindol® or placebo tablets along with written
instructions of dosing, possible side effects and a contact
number to a medical doctor in case of adverse reactions or
intolerable side effects. To ensure compliance during this
period, reminder text messages were sent to their mobile
phones three times daily. Citalopram (Seropram® Lund-
beck, Valby, Denmark) was administered intravenously as
a constant infusion over one hour where subjects received
40mg starting 30min before [11C]Cimbi-36 injection. The
16 subjects in the ATD and placebo groups received saline
infusion. Infusions were prepared by an unblinded
research nurse, but the infusions were blinded both to the
participants and to the investigators.
To achieve a reduction in serotonin levels, eight subjects
were randomized to ATD, which is a dietary method to
lower plasma tryptophan and thereby reduce the amount
available for central serotonin synthesis10,11. We used a
previously published approach10, which involves ingestionTa
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of either a gelatin-based collagen peptide (CP) mixture
(Solugel 5000®, PB Gelatins, Tessenderlo, Belgium) that is
naturally lacking tryptophan (CP-Trp), or a CP mixture
supplemented with tryptophan (CP+Trp) (Supplemen-
tary Figure S1 for full description of content). The CP-Trp
drink was prepared by adding 200ml water to 100 g
Solugel 5000®. Fifty mL artificial flavoring and ice was also
added to make the mixture palatable. The CP+Trp drink
was prepared by adding 1.2 g of L-tryptophan (Sigma-
Aldrich, Denmark) to the CP-Trp drink. The randomi-
zation and preparation of the CP mixtures were under-
taken by unblinded research administrators who were not
otherwise involved in the study. The subjects ingested the
drink at the research facilities four hours prior to the
intervention scan. The participants were instructed to
avoid protein-rich food on the day before the intervention
scan (Supplementary Methods), as well as to fast from 6
am on the intervention day. The 16 subjects in the cita-
lopram/pindolol and placebo groups also followed the low
protein diet, and were given a placebo drink four hours
before the intervention scan (CP+Trp). Tryptophan pas-
ses the blood-brain-barrier by a specific carrier for which
tryptophan competes with all other large neutral amino
acids (LNAAs)12. All subjects received a standardized diet
throughout the intervention day to ensure low tryptophan
levels and low carbohydrate intake (Supplementary
Methods), as insulin secretion preferentially stimulates
uptake of all LNAAs except for tryptophan into tissue.
This leads to depletion of LNAAs in plasma and conse-
quently an increase in the ratio between tryptophan and
the other LNAAs in plasma, which can result in elevated
levels of tryptophan entering the brain13. That is, a high
carbohydrate load can facilitate the entrance of trypto-
phan into the brain. During the intervention scan day,
plasma levels of prolactin, citalopram, tryptophan and
LNAAs were measured to verify the effects of the citalo-
pram/pindolol and ATD interventions, respectively.
Venous blood samples were analyzed for content of
tryptophan and LNAAs using HPLC (Supplementary
Methods). Tryptophan load was calculated as the ratio
between tryptophan and the sum of the other LNAA
(Trp/ΣLNAA ratio).
Magnetic Resonance Imaging
All subjects underwent MRI scans in a 3T Siemens
Magnetom Verio scanner (Siemens AG, Erlangen, Ger-
many) using a Siemens 32-channel head coil. Structural
T1- and T2-weighted images (T1 protocol: Isotropic 0.9 ×
0.9 × 0.9 mm resolution, repetition time (TR)= 1900 ms,
echo delay time (TE)= 2.32 ms, inversion time= 900 ms,
and flip angle= 9 degrees. T2 protocol: Isotropic 1 × 1 ×
1mm resolution, TR= 3200ms, TE= 409ms) were
recorded for each subject, and based on these, a seg-
mented MR-image was produced with vbm8 in SPM8
(Welcome Department of Imaging Neuroscience, Lon-
don, http://www.fil.ion.ucl.ac.uk/spm) to mask grey mat-
ter in the subsequent automated extraction of tissue time-
activity curves.
PET scanning
The 5-HT2A receptor agonist PET radioligand [
11C]
Cimbi-36 was produced for human administration, as
previously described14. All participants were scanned in a
high resolution research tomography (HRRT) PET scan-
ner (CTI/Siemens, Knoxville, TN). Following a ten minute
transmission scan a two hour emission scan was started at
the time of a [11C]Cimbi-36 bolus injection (mean injec-
ted activity: 500 ± 117 MBq; injected cold Cimbi-36 dose:
0.83 ± 0.51 µg). Attentuation correction was performed as
previously described15. [11C]Cimbi-36 scanning data were
reconstructed into 45 dynamic frames (6 × 10 s, 6 × 20 s,
6 × 60 s, 8 × 120 s, 19 × 300 s). All PET images were
motion corrected using the AIR (Automated Image
Registration, v. 5.2.5, LONI, UCLA, http://bishopw.loni.
ucla.edu/air5/) software. All frames were aligned to the
first 5-minute frame, and no partial-volume correction was
applied. Tissue time-activity curves were automatically
extracted from a set of 45 distinct regions of interest (ROIs)
using a data pipeline similar to previously reported16.
Briefly, unfiltered PET images were coregistered and
aligned to the subjects’ T1-weighted MRI image in SPM.
Coregistration and ROI placement were visually inspected
for each subject by overlaying ROIs on PET and MRI
images. A global neocortical region was defined as volume-
weighted means of the cortical ROIs: orbitofrontal cortex,
superior, middle and inferior frontal gyrus; superior, middle
and inferior temporal gyrus, sensorimotor cortex, parietal
cortex and occipital cortex. The striatum was defined as
volume-weighted means of putamen and caudate.
Radiometabolite analyses were performed using high-
performance liquid chromatography (HPLC) in order
estimate the concentrations of parent compound in
arterial plasma, which were used as input functions in
subsequent kinetic modeling. During the first 10 minutes
after injection, radioactivity in whole blood was con-
tinuously measured in 2-second intervals using an Allogg
ABSS autosampler (Allogg Technology, Mariefred, Swe-
den) counting coincidences in a lead-shielded detector
(flow: 8 mL/min). Also, blood samples were drawn
manually 2.5, 5, 10, 15, 20, 30, 40, 50, 70, 90, 105, and
120 minutes after injection. Plasma was obtained by
centrifugation (1,500 × g for 7 minutes at 4 °C) of arterial
whole blood. Radioactivity in whole blood and plasma was
measured using a well counter (Cobra 5003; Packard
Instruments, Meriden, CT, USA), which was cross-
calibrated to the high-resolution research tomography
scanner and to the autosampler. All samples were decay
corrected to the time of radioligand injection.
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Quantification of [11C]Cimbi-36 binding
Kinetic modeling was performed in PMOD version 3.0
(PMOD Technologies Inc.). The investigators were blin-
ded to which intervention group the participants were
allocated to, until data analysis was complete. The
regional binding potential (BPND) of [
11C]Cimbi-36 was
calculated using the simplified reference tissue model
(SRTM)14, and used as the primary outcome measure for
the main statistical analyses. Secondary outcome mea-
sures included regional BPNDs that were calculated from
the total distribution volumes (VT) derived from arterial
input measurements and 2-tissue compartment modeling
(2-TCM) as (VT
target−VT
cerebellum)/VT
cerebellum. Results
using 2-TCM are presented in supplemental information.
We did not find BPP suitable as an outcome measure due
to changes in free radioligand fraction in plasma (fP) as
described in the results section and Supplementary Figure
S8.
Statistical analyses
From [11C]Cimbi-36 BPNDs, the percentage difference
between baseline and intervention scans was calculated as
(BPND
intervention – BPND
baseline)/BPND
baseline for each sub-
ject. We used neocortex as our primary region of interest
based on our hypothesis that the interventions would have
global effects on serotonin levels. Also, neocortex is a high
binding region of 5-HT2A receptors. Differences in per-
cent change of neocortical [11C]Cimbi-36 BPND between
groups (citalopram/pindolol vs. placebo, and ATD vs.
placebo) were assessed with unpaired t-tests (two-tailed,
unequal variances). Normality of the data evaluated in
main analyses was assessed with Shapiro-Wilk normality
tests, which did not indicate substantial violation of
assumptions (all p > 0.2). Homogeneity of variance was
evaluated using Levene’s test. Post-hoc we analyzed group
differences in cortical and hippocampal regional [11C]
Cimbi-36 BPND. We also evaluated at thalamus and
striatum but did not find these regions suitable for eval-
uating group differences because we observed a spurious
increase in BPND from baseline to intervention in the
placebo group (of 20% and 15%, respectively9).
The effects of the interventions on prolactin and tryp-
tophan concentrations were evaluated using a between-
group two-way analysis of variance (ANOVA) of con-
centrations with time and treatment as main effects.
Differences between groups at each timepoint were
assessed with Bonferroni-corrected t-tests. The mean
absolute difference in neocortical [11C]Cimbi-36 BPND
between baseline and placebo intervention was previously
reported to be 9% and 4% with 2-TCM and SRTM,
respectively9.
Results
Demographics and [11C]Cimbi-36 radioligand injection
parameters are presented in Table 2. The mean percent
differences (±SD) in neocortical [11C]Cimbi-36 BPND
from baseline to intervention were 7.4 ± 16.0% after cita-
lopram/pindolol and 0.6 ± 7.2% after ATD (Fig. 1).
Unpaired t-tests revealed no statistically significant dif-
ferences in percent change of neocortical [11C]Cimbi-36
BPND between placebo and citalopram/pindolol (t(9.7)=
0.7, p= 0.4), or between placebo and ATD (t(12.9)= 1.6,
p= 0.5). Similar results were found when 2-TCM was
used to estimate [11C]Cimbi-36 BPND (Supplementary
Figure S2). As seen in Fig. 1, there was large within-
subject variation of [11C]Cimbi-36 binding in the citalo-
pram/pindolol group compared with placebo (Levene’s
test F(1)= 9.9, p= 0.007). The change in neocortical
BPND from baseline to intervention in each subject are
shown in Supplementary Figures S3–S5.
Post hoc regional analyses revealed a significant differ-
ence in percent change of hippocampal [11C]Cimbi-36
BPND between placebo and Citalopram/Pindolol
(t(13.7)= 2.4, p= 0.03, Supplementary Figure S6–S7), but
Table 2 Demographics and [11C]Cimbi-36 radioligand injection parameters at baseline and intervention PET scans
Placebo Citalopram/Pindolol ATD
Number of subjects 8 (4 males) 8 (4 males) 8 (4 males)
Age (years) 22.0 ± 2.5 21.9 ± 2.0 22.3 ± 3.2
Body Mass Index (kg/m2) 23.6 ± 2.5 23.9 ± 1.9 22.6 ± 1.9
Interscan interval (days) 30.6 ± 15.5 22.4 ± 2.8 27.6 ± 17.1
Baseline Intervention Baseline Intervention Baseline Interventiona
Injected dose (MBq) 509 ± 95 581 ± 27 477 ± 142 574 ± 37 554 ± 54 554 ± 52
Injected mass (µg) 0.9 ± 0.5 0.9 ± 0.5 0.9 ± 0.6 0.7 ± 0.5 0.9 ± 0.5 1.0 ± 0.4
Free fraction in plasma, fP (%) 2.7 ± 0.4 3.7 ± 0.5 2.9 ± 0.5 3.4 ± 0.8 3.0 ± 0.5 3.0 ± 0.8
Values represent mean ± standard deviation
a One female subject excluded due to adverse reaction during the baseline scan
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not between placebo and ATD (t(5.8)= -0.7, p= 0.5). The
mean percent difference in hippocampal BPND from
baseline to intervention in the Citalopram/Pindolol group
was −25.5 ± 25.2%, indicating increased serotonin levels
in this region. We found no significant group differences
in percent change of [11C]Cimbi-36 BPND in any of the
cortical regions of interest (frontal, temporal and parietal
cortex, anterior and posterior cingulate).
The effects of citalopram/pindolol were confirmed by
significant elevation of plasma prolactin measured one
hour after SSRI infusion (p < 0.01, Fig. 2a), and serum
citalopram measured 50 and 120min after radioligand
injection (citalopram infusion started 30min prior to
radioligand injection and lasted for one hour) (Fig. 2b).
Likewise, the effects of ATD were confirmed by sig-
nificantly decreased concentrations of plasma tryptophan
compared with subjects receiving the placebo drink con-
taining all amino acids (p < 0.001, Fig. 2c). The mean
percent change in the ratio of tryptophan to the other
LNAAs (tryptophan load) from before to ~4 h after
ingestion of the drink was −72.2 ± 7.2% in the ATD
group, 40.4 ± 21.5% in the placebo group and 35.4 ± 7.2%
in the citalopram/pindolol group.
Free radioligand fraction in plasma (fP) was significantly
higher at intervention compared with baseline in the two
groups receiving placebo amino acid drinks (Supple-
mentary Figure S8). This change in fP was not associated
with changes in BPND from baseline to intervention across
groups (slope estimate: −0.002, 95% confidence interval:
[−0.28; 0.28], p= 0.99, Fig. 3), nor in each group analyzed
separately (placebo group: p= 0.09, ATD group: p= 0.99,
citalopram/pindolol group: p= 0.12).
Discussion
This study examined the sensitivity of the 5-HT2A
receptor agonist radioligand [11C]Cimbi-36 to changes in
endogenous serotonin concentrations in the human brain.
Contrary to our hypothesis, neither ATD nor a combi-
nation of citalopram and pindolol elicited unidirectional
changes in serotonin levels that were detectable with [11C]
Cimbi-36 PET, at least not with the current sample size.
Interestingly, we observed large within-group variation in
[11C]Cimbi-36 binding after intervention with citalopram
and pindolol as compared to placebo and ATD.
Studies in pigs and nonhuman primates show reductions
in [11C]Cimbi-36 binding after interventions that increase
serotonin levels4,17. Using microdialysis and [11C]Cimbi-36
PET in pigs, the potent serotonin releaser fenfluramine
produced an increase in extracellular serotonin levels of
1123% relative to baseline, whereas citalopram in combi-
nation with pindolol led to an increase of 441% of serotonin
baseline level, corresponding to a 5-HT2A receptor occu-
pancy of 44% with fenfluramine and 28% with citalopram
and pindolol measured with [11C]Cimbi-3617. This corre-
lation between pharmacologically induced changes in
extracellular serotonin levels and changes in [11C]Cimbi-36
PET signal indicates that at least in pigs, [11C]Cimbi-36 is
sensitive to changes in endogenous serotonin levels. In
nonhuman primates, fenfluramine also decreased [11C]
Cimbi-36 binding by 26–62%4. Given these observations in
animals, we expected that [11C]Cimbi-36 binding would be
reduced following intervention with citalopram/pindolol
also in humans and we suspect that when given acutely, and
in the doses used here, citalopram has variable effects on
serotonin levels in the brain. Other human PET studies
evaluating the effects of acute intervention with SSRI sup-
port this interpretation; two recent studies reported
increased [11C]CUMI-101 (5-HT1A receptor radioligand)
and [11C]AZ10419369 (5-HT1B receptor partial agonist)
binding in projection areas after acute SSRI intervention
(10mg citalopram intravenously and a single oral dose of
20mg escitalopram, respectively) suggesting a reduction of
serotonin levels6,7. The authors suggested that the increase
in cortical 5-HT1A receptor binding after citalopram is
driven by an action in the dorsal raphe nuclei, i.e., acute
SSRI produces increases in serotonin levels in the raphe
nuclei which then decreases firing rates in postsynaptic
regions6. Microdialysis and neurophysiological studies in
rodents have shown an increase in serotonin concentration
in the raphe nuclei after administration of an SSRI, leading
to attenuated release of serotonin in projection areas18,19
interpreted as caused by 5-HT1A autoreceptor regulation.
One speculation is that the autoregulation of serotonergic
firing may be particularly strong in the human brain, which
was also the reason for our decision to inhibit the raphe
nuclei-mediated response to SSRI by blocking the 5-HT1A
autoreceptors with pindolol. However, the chosen dose of
pindolol may only have been sufficient in some of the
participants, which would be consistent with the larger
within-subject variation of [11C]Cimbi-36 binding
Δ
Fig. 1 Effects of citalopram/pindolol (Cit/Pin) and acute tryptophan
depletion (ATD) intervention on [11C]Cimbi-36 binding potential
(BPND) in neocortex. Difference in outcome is calculated as
(BPND
intervention−BPND
baseline)/ BPND
baseline for each subject
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Fig. 2 Effects of interventions on prolactin, citalopram and tryptophan levels. Time on the x-axis is referenced to the time of [11C]Cimbi-36
injection. a Plasma prolactin levels relative to time of [11C]Cimbi-36 injection. **p < 0.01 indicates Bonferroni-corrected post-test between groups
(citalopram/pindolol versus ATD as well as placebo groups) in a 2-way ANOVA of prolactin concentration with time and treatment as main effects.
Normal interval for plasma prolactin: 70-440mIU/L. b Serum citalopram concentrations relative to time of [11C]Cimbi-36 injection. Citalopram was
given intravenously for one hour starting 30 minutes before time of injection. c. Plasma tryptophan levels relative to time of [11C]Cimbi-36 injection.
***p < 0.001 indicate Bonferroni-corrected post-test between groups (ATD versus citalopram/pindolol as well as placebo groups) in a 2-way ANOVA
of tryptophan concentrations with time and treatment as main effects
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compared with placebo. Alternatively, we did manage to
block the autoreceptors sufficiently, but there was a large
interindividual variability in brain serotonin levels in
response to SSRIs. In the latter case, our observation has a
potential impact for the understanding of patient responses
to SSRI. For example, SSRI treatment ameliorates depres-
sive symptoms in some patients but not all20,21. The current
sample size does not permit a meaningful analysis of
potential causes of the larger variation in the citalopram/
pindolol group, but may involve genetic variants, differences
in pharmacodynamics, or other factors.
We used a global neocortical region in which [11C]
Cimbi-36 binds selectively to 5-HT2A receptors. In our
post hoc regional analyses, we found a significant decrease
in hippocampal BPND after Citalopram/Pindolol. This
suggests that in hippocampus, Citalopram/Pindolol is
associated with an increase in serotonin that is subject to
less interindividual variation. Interestingly, hippocampal
volume in depressed patients increased after treatment
with citalopram22. Alternatively, the decline in hippo-
campal BPND could be caused by its high density of 5-
HT2C receptors. Recent studies have found that [
11C]
Cimbi-36 (in addition to 5-HT2A receptors) also binds to
5-HT2C receptors in hippocampus in the monkey
23 and
human brain9.
ATD is an established method for manipulating brain
serotonin function, with effects on cognition and beha-
vior24. In rodents, acute and chronic tryptophan depletion
reduce central serotonin levels25–28. Using this technique,
we compared [11C]Cimbi-36 BPND following ATD and a
placebo condition, hypothesizing that if [11C]Cimbi-36
binding is susceptible to competition with endogenous
serotonin, we would observe an increase in [11C]Cimbi-36
BPND after ATD. We found no significant changes in
BPND, suggesting that the reduction in endogenous ser-
otonin levels elicited by ATD was not sufficient to pro-
duce a measurable increase in the binding of [11C]Cimbi-
36. Indeed, the effect of ATD on central serotonin levels
has been debated29,30, and the extent by which ATD alters
serotonin levels in humans may vary across individuals
and contexts30. Previous PET studies investigating the
effects of ATD on components of the serotonin system
have produced mixed results. Studies in healthy controls
report no ATD induced changes in 5-HT2A receptor
binding ([11C]MDL100907)31, or serotonin transporter
binding ([11C]DASB)32,33, whereas prefrontal monoamine
oxidase A density was decreased following ATD34. In a
study of patients with major depressive disorder, regional
5-HT1A receptor binding ([
18F]-MPPF) was not altered
after ATD, although six of the eight patients had a tran-
sient relapse in depressive symptoms35. Studies examining
patients with remitted major depressive disorder found
that ATD induced a transient return of depressive
symptoms36,37, along with decreased 5-HT2 receptor
binding of [18F]Setoperone in patients36, and augmented
regional cerebral glucose utilization in patients but not in
controls37. We did not observe any effects of ATD on
mood in our healthy participants (reported in Stenbæk
et al.10). One interpretation of the current data is that
these healthy participants, who showed no signs of psy-
chopathology, may be resilient to ATD and are able to
maintain stable serotonin levels and mood. Alternatively,
ATD did not elicit a sufficient decrease in serotonin levels
to be detected with our sample size.
On intervention days, all participants regardless of
treatment group received a drink with a high load of
amino acids. In the two groups receiving placebo drinks
(containing tryptophan) radioligand plasma protein
binding was lower on intervention days compared with
baseline. Tryptophan in plasma is bound to albumin, with
approximately 5% being left free and available for trans-
port into the brain13. We suggest that the high load of
amino acids, in particular tryptophan, was responsible for
the increase in fP. A possible explanation is that compe-
tition between tryptophan and [11C]Cimbi-36 binding
with plasma binding proteins (e.g. albumin) occurs,
resulting in a larger proportion of free [11C]Cimbi-36 in
plasma. Few other PET studies have reported effects of
tryptophan on fP. Talbot et al.
31 report that the fP of [
11C]
MDL100907 did not differ between placebo and ATD31.
In another study investigating binding of the serotonin
transporter tracer [11C]DASB after intervention with
Fig. 3 Association between the percent changes in fP from baseline to
intervention and percent change in neocortical BPND from baseline to
intervention. Cit-Pin: citalopram/pindolol
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ATD, there was no difference in fP of [
11C]DASB between
the two conditions, but there was a small decrease in both
VT and BP from baseline to intervention that was related
to a concomitant difference in fP of similar magnitude
32.
In the latter study, the change in BP and VT became non-
significant when corrected for fP, suggesting that the effect
may have been driven by changes in fP
32. We used BPND
as the outcome measure; this parameter is independent of
changes in fP, and as such, we consider the findings of this
study to reflect changes in 5-HT2A receptor availability.
A few limitations of this study should be mentioned.
The study includes a limited sample size, but the low test-
retest variability and investigation of the same individuals
before and after the intervention is a strong design. Even
though we cannot exclude that the variability observed in
the citalopram/pindolol group can be attributed to mea-
surement error we find this unlikely, given the low
variability in the placebo group. Another limitation is that
the increase in both the tryptophan concentration and the
tryptophan load (Trp/ΣLNAA ratio) in the groups
receiving placebo amino acid drinks may have affected the
cerebral serotonin levels in these participants, potentially
interfering with the effects of SSRI treatment. Likewise,
pindolol treatment may also have affected the cerebral
serotonin levels, putatively interfering the effect of SSRI.
In conclusion, the data presented in this study suggest
that neither ATD nor a combination of citalopram and
pindolol elicit acute unidirectional and global changes in
extracellular serotonin levels that are sufficient to be
detected by [11C]Cimbi-36 PET. Recent data suggest that
[11C]Cimbi-36 is sensitive to changes in endogenous
serotonin levels only when serotonin release is sufficiently
high, e.g. amphetamine challenge38. The large variability
in [11C]Cimbi-36 binding after citalopram/pindolol could
reflect interindividual differences in brain serotonin levels
after an acute SSRI intervention. This observation may
have a potential impact for the understanding of patient
responses to SSRIs, which should be explored in future
studies.
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